$76.22
1.87% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US2183521028
Symbol
CORT

Corcept Therapeutics Incorporated. Stock price

$76.22
+13.32 21.18% 1M
+20.13 35.89% 6M
+25.83 51.26% YTD
+47.34 163.92% 1Y
+55.80 273.26% 3Y
+61.24 408.81% 5Y
+70.36 1,200.68% 10Y
Nasdaq, Closing price Tue, May 20 2025
+1.40 1.87%
ISIN
US2183521028
Symbol
CORT
Sector
Industry

Key metrics

Market capitalization $8.08b
Enterprise Value $7.77b
P/E (TTM) P/E ratio 66.16
EV/FCF (TTM) EV/FCF 43.84
EV/Sales (TTM) EV/Sales 11.33
P/S ratio (TTM) P/S ratio 11.79
P/B ratio (TTM) P/B ratio 11.82
Revenue growth (TTM) Revenue growth 30.93%
Revenue (TTM) Revenue $685.45m
EBIT (operating result TTM) EBIT $110.87m
Free Cash Flow (TTM) Free Cash Flow $177.16m
Cash position $322.76m
EPS (TTM) EPS $1.15
P/E forward 55.30
P/S forward 8.99
EV/Sales forward 8.64
Short interest 16.76%
Show more

Is Corcept Therapeutics Incorporated. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Corcept Therapeutics Incorporated. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

Buy
100%

Financial data from Corcept Therapeutics Incorporated.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
685 685
31% 31%
100%
- Direct Costs 11 11
41% 41%
2%
675 675
31% 31%
98%
- Selling and Administrative Expenses 313 313
65% 65%
46%
- Research and Development Expense 249 249
23% 23%
36%
113 113
9% 9%
16%
- Depreciation and Amortization 1.68 1.68
0% 0%
0%
EBIT (Operating Income) EBIT 111 111
9% 9%
16%
Net Profit 132 132
13% 13%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Corcept Therapeutics Incorporated. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corcept Therapeutics Incorporated. Stock News

Neutral
Investors Business Daily
one day ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
Seeking Alpha
15 days ago
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrinology Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Roberto Vieira - President, Oncology Bill Guyer - Chief Development Officer Conference Call Participants Edward Nas...
Neutral
Business Wire
15 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat serious endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2025. Financial Results “In the firs...
More Corcept Therapeutics Incorporated. News

Company Profile

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Head office United States
CEO Joseph Belanoff
Employees 500
Founded 1998
Website www.corcept.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today